scholarly journals Mo1265 WATS TESTING INCREASES DETECTION OF RECURRENT INTESTINAL METAPLASIA FOLLOWING COMPLETE ERADICATION OF INTESTINAL METAPLASIA IN TREATED BARRETT’S ESOPHAGUS WITH LOW-GRADE DYSPLASIA, HIGH-GRADE DYSPLASIA, OR INTRAMUCOSAL ADENOCARCINOMA

2020 ◽  
Vol 91 (6) ◽  
pp. AB406-AB407
Author(s):  
Cary C. Cotton ◽  
David M. Chaletsky ◽  
Brian Moloney ◽  
Zubair A. Malik ◽  
Arvind J. Trindade ◽  
...  
Author(s):  
K Y Song ◽  
A J Henn ◽  
A A Gravely ◽  
H Mesa ◽  
S Sultan ◽  
...  

SUMMARY Patients with Barrett's esophagus (BE) and low-grade dysplasia (LGD) are at increased risk of esophageal adenocarcinoma (EAC), although many regress to nondysplastic BE. This has significant clinical importance for patients being considered for endoscopic eradication therapy. Our aim is to determine the risk for progression in patients with confirmed persistent LGD. We performed a single-center retrospective cohort study of patients with BE and confirmed LGD between 2006 and 2016. Confirmed LGD was defined as LGD diagnosed by consensus conference with an expert GI pathologist or review by an expert GI pathologist and persistence as LGD present on subsequent endoscopic biopsy. The primary outcome was the incidence rate of HGD (high-grade dysplasia)/EAC. Secondary outcomes included risk factors for dysplastic progression. Risk factors for progression were assessed using univariate and multivariate analysis with logistic regression. Of 69 patients (mean age 65.2 years) with confirmed LGD were included. In total, 16 of 69 patients (23.2%) with LGD developed HGD/EAC during a median follow-up of 3.74 years (IQR, 1.24–5.45). For persistent confirmed LGD, the rate was 6.44 (95% confidence interval (CI), 2.61–13.40) compared to 2.61 cases per 100 patient-years (95% CI, 0.83–6.30) for nonpersistent LGD. Persistent LGD was found in only 29% of patients. Persistent LGD was an independent risk factor for the development of HGD/EAC (OR 4.18; [95% CI, 1.03–17.1]). Persistent confirmed LGD, present in only 1/3 of patients, was an independent risk factor for the development of HGD/EAC. Persistence LGD may be useful in decision making regarding the management of BE.


2016 ◽  
Vol 83 (5) ◽  
pp. AB552
Author(s):  
Allon Kahn ◽  
Jonathan K. Callaway ◽  
Mohanad Al-Qaisi ◽  
David E. Fleischer ◽  
George E. Burdick ◽  
...  

2017 ◽  
Vol 152 (5) ◽  
pp. S449-S450
Author(s):  
Joel H. Rubenstein ◽  
Akbar K. Waljee ◽  
Jacques Bergman ◽  
Michael Vieth ◽  
Sachin B. Wani

Sign in / Sign up

Export Citation Format

Share Document